Substantia Nigra Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The substantia nigra (SN) is a midbrain structure critical for motor control and reward processing. It contains dopaminergic neurons whose degeneration is the hallmark of [Parkinson's disease (PD)parkinsons-disease), making it one of the most studied structures in neurodegeneration research. [1]
The substantia nigra is divided into two main regions with distinct functions and vulnerability patterns: [2]
| Taxonomy | ID | Name / Label |
|---|
The SNc neurons project to the striatum (caudate nucleus and putamen) forming the nigrostriatal dopamine pathway, which is critical for: [3]
SNc neurons also project to: [4]
| Cell Type | Characteristics | Vulnerability | [5]
|-----------|-----------------|---------------| [6]
| Dopaminergic neurons | Large (30-50 μm), pigmented with neuromelanin | Highly vulnerable in PD | [7]
| GABAergic interneurons | Smaller, local inhibition | Relatively spared | [8]
Single-cell studies have identified distinct SNc subpopulations: [9]
The SN controls multiple overlapping systems: [10]
The selective vulnerability of SNc dopaminergic neurons in PD involves multiple interconnected mechanisms: [11]
| Disease | SN Involvement |
|---|---|
| Progressive Supranuclear Palsy | Moderate SNc loss, SNr involvement |
| Multiple System Atrophy | Variable SN degeneration |
| Dementia with Lewy Bodies | Significant SN pathology |
| Huntington's Disease | SNc changes, dopamine dysfunction |
| Parkinsonism-Dementia Complex of Guam | SN vulnerability |
The study of Substantia Nigra Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Tags: substantia nigra, dopamine, Parkinson's disease, neurodegeneration, basal ganglia, motor control, selective vulnerability
Surmeier DJ, Obross J, Pierce J, et al. Determinants of nigral dopaminergic neuron vulnerability. 2017. ↩︎
Kalia LV, Lang AE. Parkinson's disease. 2015. ↩︎
Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. 1999. ↩︎
Björklund A, Dunnett SB. Dopamine neuron systems in the brain: new insights. 2007. ↩︎
Hornykiewicz O. dopamine and Parkinson's disease: a historical perspective. 2010. ↩︎
Brichta L, Greengard P. Molecular determinants of selective dopaminergic vulnerability. 2014. ↩︎
Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. 2010. ↩︎
Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson's disease. 2013. ↩︎
Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. 2013. ↩︎
Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. 2017. ↩︎
Jellinger KA. The pathomechanisms of nigral neuron loss in Parkinson's disease. 2019. ↩︎